Fatty acids regulate endothelial lipase and inflammatory markers in macrophages and in mouse aorta: A role for PPARγ

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 32, Issue 12, 2012, Pages 2929-2937

  Jung, Un Ju ^a   Torrejon, Claudia ^a   Chang, Chuchun L ^a   Hamai, Hiroko ^b   Worgall, Tilla S ^a,b   Deckelbaum, Richard J ^a,b  

^a Columbia University ^*  (United States)

^b Och Spine at New York Presbyterian Hospitals   (United States)

Author keywords

atherosclerosis; endothelial lipase; inflammation; n 3 fatty acids; PPAR

Indexed keywords

2 CHLORO 5 NITROBENZANILIDE; ICOSAPENTAENOIC ACID; INTERLEUKIN 10; INTERLEUKIN 12P40; INTERLEUKIN 6; LOW DENSITY LIPOPROTEIN; MACROPHAGE ENDOTHELIAL LIPASE; MANNOSE RECEPTOR; OMEGA 3 FATTY ACID; PALMITIC ACID; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; ROSIGLITAZONE; TOLL LIKE RECEPTOR 4; TRIACYLGLYCEROL LIPASE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; CYTOKINE RESPONSE; ENZYME REGULATION; MALE; MOUSE; NONHUMAN; PERITONEUM MACROPHAGE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION;

ANIMALS; AORTA; BIOLOGICAL MARKERS; CELL LINE; DOSE-RESPONSE RELATIONSHIP, DRUG; EICOSAPENTAENOIC ACID; FATTY ACIDS; FATTY ACIDS, OMEGA-3; INTERLEUKIN-12 SUBUNIT P40; INTERLEUKIN-6; LIPASE; LIPOPOLYSACCHARIDES; MACROPHAGES, PERITONEAL; MALE; MICE; MICE, KNOCKOUT; MODELS, ANIMAL; PALMITIC ACID; PPAR GAMMA; RECEPTORS, LDL; TOLL-LIKE RECEPTOR 4;

EID: 84870064706     PISSN: 10795642     EISSN: 15244636     Source Type: Journal    
DOI: 10.1161/ATVBAHA.112.300188     Document Type: Article

References (51)

1. Ross R. Atherosclerosis-an inflammatory disease. N Engl J Med. 1999;340:115-126.
2. Hansson GK, Libby P. The immune response in atherosclerosis: a doubleedged sword. Nat Rev Immunol. 2006;6:508-519. (Pubitemid 43980523)
3. Watts GF, Jackson P, Burke V, Lewis B. Dietary fatty acids and progression of coronary artery disease in men. Am J Clin Nutr. 1996;64:202-209. (Pubitemid 26250840)
4. Kromhout D. Fatty acids, antioxidants, and coronary heart disease from an epidemiological perspective. Lipids. 1999;34:S27-S31.
5. Thies F, Garry JM, Yaqoob P, Rerkasem K, Williams J, Shearman CP, Gallagher PJ, Calder PC, Grimble RF. Association of n3 polyunsaturated fatty acids with stability of atherosclerotic plaques: a randomised controlled trial. Lancet. 2003;361:477-485. (Pubitemid 36173713)
6. Wang C, Harris WS, Chung M, Lichtenstein AH, Balk EM, Kupelnick B, Jordan HS, Lau J. n3 Fatty acids from fish or fishoil supplements, but not alphalinolenic acid, benefit cardiovascular disease outcomes in primary and secondaryprevention studies: a systematic review. Am J Clin Nutr. 2006;84:5-17. (Pubitemid 44699166)
7. Matsumoto M, Sata M, Fukuda D, Tanaka K, Soma M, Hirata Y, Nagai R. Orally administered eicosapentaenoic acid reduces and stabilizes atherosclerotic lesions in ApoEdeficient mice. Atherosclerosis. 2008;197:524-533. (Pubitemid 351417875)
8. Azumi H, Hirata K, Ishida T, Kojima Y, Rikitake Y, Takeuchi S, Inoue N, Kawashima S, Hayashi Y, Itoh H, Quertermous T, Yokoyama M. Immunohistochemical localization of endothelial cellderived lipase in atherosclerotic human coronary arteries. Cardiovasc Res. 2003;58:647-654. (Pubitemid 36694450)
9. Ishida T, Choi SY, Kundu RK, Spin J, Yamashita T, Hirata K, Kojima Y, Yokoyama M, Cooper AD, Quertermous T. Endothelial lipase modulates susceptibility to atherosclerosis in apolipoproteinEdeficient mice. J Biol Chem. 2004;279:45085-45092. (Pubitemid 39430923)
10. Yasuda T, Hirata K, Ishida T, Kojima Y, Tanaka H, Okada T, Quertermous T, Yokoyama M. Endothelial lipase is increased by inflammation and promotes LDL uptake in macrophages. J Atheroscler Thromb. 2007;14:192-201.
11. Kojma Y, Hirata K, Ishida T, Shimokawa Y, Inoue N, Kawashima S, Quertermous T, Yokoyama M. Endothelial lipase modulates monocyte adhesion to the vessel wall. A potential role in inflammation. J Biol Chem. 2004;279:54032-54038. (Pubitemid 40053136)
12. Wang X, Jin W, Rader DJ. Upregulation of macrophage endothelial lipase by tolllike receptors 4 and 3 modulates macrophage interleukin10 and 12 production. Circ Res. 2007;100:1008-1015. (Pubitemid 46598925)
13. Nagy L, Tontonoz P, Alvarez JG, Chen H, Evans RM. Oxidized LDL regulates macrophage gene expression through ligand activation of PPARgamma. Cell. 1998;93:229-240. (Pubitemid 28180856)
14. Tontonoz P, Nagy L, Alvarez JG, Thomazy VA, Evans RM. PPARgamma promotes monocyte/macrophage differentiation and uptake of oxidized LDL. Cell. 1998;93:241-252. (Pubitemid 28180857)
15. Li L, Beauchamp MC, Renier G. Peroxisome proliferatoractivated receptor alpha and gamma agonists upregulate human macrophage lipoprotein lipase expression. Atherosclerosis. 2002;165:101-110. (Pubitemid 35223171)
16. Jiang C, Ting AT, Seed B. PPARgamma agonists inhibit production of monocyte inflammatory cytokines. Nature. 1998;391:82-86. (Pubitemid 28079219)
17. Babaev VR, Yancey PG, Ryzhov SV, Kon V, Breyer MD, Magnuson MA, Fazio S, Linton MF. Conditional knockout of macrophage PPARgamma increases atherosclerosis in C57BL/6 and lowdensity lipoprotein receptordeficient mice. Arterioscler Thromb Vasc Biol. 2005;25:1647-1653. (Pubitemid 41098935)
18. Moore KJ, Fitzgerald ML, Freeman MW. Peroxisome proliferatoractivated receptors in macrophage biology: friend or foe? Curr Opin Lipidol. 2001;12:519-527. (Pubitemid 32980300)
19. Thieringer R, FenykMelody JE, Le Grand CB, Shelton BA, Detmers PA, Somers EP, Carbin L, Moller DE, Wright SD, Berger J. Activation of peroxisome proliferatoractivated receptor gamma does not inhibit IL6 or TNFalpha responses of macrophages to lipopolysaccharide in vitro or in vivo. J Immunol. 2000;164:1046-1054. (Pubitemid 30043733)
20. Guyton K, Bond R, Reilly C, Gilkeson G, Halushka P, Cook J. Differential effects of 15deoxydelta(12,14)prostaglandin J2 and a peroxisome proliferatoractivated receptor gamma agonist on macrophage activation. J Leukoc Biol. 2001;69:631-638. (Pubitemid 32294848)
21. Rossi A, Kapahi P, Natoli G, Takahashi T, Chen Y, Karin M, Santoro MG. Antiinflammatory cyclopentenone prostaglandins are direct inhibitors of IkappaB kinase. Nature. 2000;403:103-108. (Pubitemid 30038530)
22. Chawla A, Barak Y, Nagy L, Liao D, Tontonoz P, Evans RM. PPARgamma dependent and independent effects on macrophagegene expression in lipid metabolism and inflammation. Nat Med. 2001;7:48-52. (Pubitemid 32095641)
23. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med. 2007;356:2457-2471. (Pubitemid 46919772)
24. Rosen CJ. The rosiglitazone story-lessons from an FDA Advisory Committee meeting. N Engl J Med. 2007;357:844-846. (Pubitemid 47347317)
25. Seo T, Qi K, Chang C, Liu Y, Worgall TS, Ramakrishnan R, Deckelbaum RJ. Saturated fatrich diet enhances selective uptake of LDL cholesteryl esters in the arterial wall. J Clin Invest. 2005;115:2214-2222. (Pubitemid 41134164)
26. Chang CL, Seo T, Matsuzaki M, Worgall TS, Deckelbaum RJ. n3 fatty acids reduce arterial LDLcholesterol delivery and arterial lipoprotein lipase levels and lipase distribution. Arterioscler Thromb Vasc Biol. 2009;29:555-561.
27. Chang CL, Seo T, Du CB, Accili D, Deckelbaum RJ. n3 Fatty acids decrease arterial lowdensity lipoprotein cholesterol delivery and lipoprotein lipase levels in insulinresistant mice. Arterioscler Thromb Vasc Biol. 2010;30:2510-2517.
28. Neve BP, Fruchart JC, Staels B. Role of the peroxisome proliferatoractivated receptors (PPAR) in atherosclerosis. Biochem Pharmacol. 2000;60:1245-1250.
29. LopesVirella MF. Interactions between bacterial lipopolysaccharides and serum lipoproteins and their possible role in coronary heart disease. Eur Heart J. 1993;14:118-124.
30. Thorp E, Kuriakose G, Shah YM, Gonzalez FJ, Tabas I. Pioglitazone increases macrophage apoptosis and plaque necrosis in advanced atherosclerotic lesions of nondiabetic lowdensity lipoprotein receptornull mice. Circulation. 2007;116:2182-2190. (Pubitemid 350060356)
31. Sakamoto J, Kimura H, Moriyama S, Odaka H, Momose Y, Sugiyama Y, Sawada H. Activation of human peroxisome proliferatoractivated receptor (PPAR) subtypes by pioglitazone. Biochem Biophys Res Commun. 2000;278:704-711.
32. Lee JY, Hwang DH. Docosahexaenoic acid suppresses the activity of peroxisome proliferatoractivated receptors in a colon tumor cell line. Biochem Biophys Res Commun. 2002;298:667-674. (Pubitemid 35356792)
33. Edwards IJ, O'Flaherty JT. Omega3 Fatty Acids and PPARgamma in Cancer. PPAR Res. 2008;2008:358052.
34. Khodadadi I, Griffin B, Thumser A. Differential effects of longchain fatty acids and clofibrate on gene expression profiles in cardiomyocytes. Arch Iranian Med. 2008;11:42-49. (Pubitemid 351233549)
35. Allman M, Gaskin L, Rivera CA. CCl4induced hepatic injury in mice fed a Western diet is associated with blunted healing. J Gastroenterol Hepatol. 2010;25:635-643.
36. Zhou J, Wilson KM, Medh JD. Genetic analysis of four novel peroxisome proliferator activated receptorgamma splice variants in monkey macrophages. Biochem Biophys Res Commun. 2002;293:274-283. (Pubitemid 34694203)
37. Sauma L, Stenkula KG, Kjølhede P, Strålfors P, Söderström M, Nystrom FH. PPARgamma response element activity in intact primary human adipocytes: effects of fatty acids. Nutrition. 2006;22:60-68. (Pubitemid 43175786)
38. Schoonjans K, PeinadoOnsurbe J, Lefebvre AM, Heyman RA, Briggs M, Deeb S, Staels B, Auwerx J. PPARalpha and PPARgamma activators direct a distinct tissuespecific transcriptional response via a PPRE in the lipoprotein lipase gene. EMBO J. 1996;15:5336-5348. (Pubitemid 26336216)
39. Wu X, Huang H, Tang F, Le K, Xu S, Liu P. Regulated expression of endothelial lipase in atherosclerosis. Mol Cell Endocrinol. 2010;315:233-238.
40. Khanna AK. Enhanced susceptibility of cyclin kinase inhibitor p21 knockout mice to high fat diet induced atherosclerosis. J Biomed Sci. 2009;16:66.
41. Kambayashi T, Jacob CO, Strassmann G. IL4 and IL13 modulate IL10 release in endotoxinstimulated murine peritoneal mononuclear phagocytes. Cell Immunol. 1996;171:153-158. (Pubitemid 26349138)
42. Huber SA, Sakkinen P, Conze D, Hardin N, Tracy R. Interleukin6 exacerbates early atherosclerosis in mice. Arterioscler Thromb Vasc Biol. 1999;19:2364-2367. (Pubitemid 29477837)
43. Davenport P, Tipping PG. The role of interleukin4 and interleukin12 in the progression of atherosclerosis in apolipoprotein Edeficient mice. Am J Pathol. 2003;163:1117-1125. (Pubitemid 37040147)
44. Pinderski Oslund LJ, Hedrick CC, Olvera T, Hagenbaugh A, Territo M, Berliner JA, Fyfe AI. Interleukin10 blocks atherosclerotic events in vitro and in vivo. Arterioscler Thromb Vasc Biol. 1999;19:2847-2853. (Pubitemid 30029809)
45. Renier G, Skamene E, DeSanctis J, Radzioch D. Dietary n3 polyunsaturated fatty acids prevent the development of atherosclerotic lesions in mice. Modulation of macrophage secretory activities. Arterioscler Thromb. 1993;13:1515-1524. (Pubitemid 23303406)
46. Qiu G, Ho AC, Yu W, Hill JS. Suppression of endothelial or lipoprotein lipase in THP1 macrophages attenuates proinflammatory cytokine secretion. J Lipid Res. 2007;48:385-394. (Pubitemid 46220605)
47. Jin W, Millar JS, Broedl U, Glick JM, Rader DJ. Inhibition of endothelial lipase causes increased HDL cholesterol levels in vivo. J Clin Invest. 2003;111:357-362. (Pubitemid 36182212)
48. Lee JY, Plakidas A, Lee WH, Heikkinen A, Chanmugam P, Bray G, Hwang DH. Differential modulation of Tolllike receptors by fatty acids: preferential inhibition by n3 polyunsaturated fatty acids. J Lipid Res. 2003;44:479-486. (Pubitemid 37279695)
49. Zhao Y, JoshiBarve S, Barve S, Chen LH. Eicosapentaenoic acid prevents LPSinduced TNFalpha expression by preventing NFkappaB activation. J Am Coll Nutr. 2004;23:71-78. (Pubitemid 38200837)
50. Ajuwon KM, Spurlock ME. Palmitate activates the NFkappaB transcription factor and induces IL6 and TNFalpha expression in 3T3L1 adipocytes. J Nutr. 2005;135:1841-1846. (Pubitemid 41099739)
51. Harris WS. n3 fatty acids and lipoproteins: comparison of results from human and animal studies. Lipids. 1996;31:243-252. (Pubitemid 26094301)